Physician profile
Rachael Stein
NPI 1992787519
$4,558.79
in general payments reported to CMS, 2019-2025
23 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $690 · 2023: $896 · 2024: $1,093 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,427 · Education: $35.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,426.64 |
| Education | $35.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.55 | 2021-2025 | |
| Janssen Biotech, INC. | $551.30 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $465.09 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $240.51 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $236.49 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $221.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $178.58 | 2021-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.48 | 2021-2024 | Xifaxan |
| Pfizer INC. | $170.40 | 2024-2025 | |
| Lilly USA, LLC | $127.85 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $97.20 | 2021-2023 | Rebyota |
| Genzyme Corporation | $88.86 | 2022-2024 | |
| Redhill Biopharma INC. | $68.35 | 2021-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $62.18 | 2022-2023 | Ocaliva |
| Braintree Laboratories, INC. | $59.56 | 2024 | Sutab, Suflave |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $54.33 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $48.96 | 2022-2023 | Ibsrela |
| Qol Medical, LLC | $44.63 | 2023 | Sucraid |
| Merck Sharp & Dohme LLC | $36.51 | 2021 | |
| Aimmune Therapeutics, INC. | $32.98 | 2025 | Vowst |
| Celltrion USA INC. | $24.74 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $20.26 | 2023 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.